JP2015516450A5 - - Google Patents

Download PDF

Info

Publication number
JP2015516450A5
JP2015516450A5 JP2015511956A JP2015511956A JP2015516450A5 JP 2015516450 A5 JP2015516450 A5 JP 2015516450A5 JP 2015511956 A JP2015511956 A JP 2015511956A JP 2015511956 A JP2015511956 A JP 2015511956A JP 2015516450 A5 JP2015516450 A5 JP 2015516450A5
Authority
JP
Japan
Prior art keywords
pain
weeks
refers
treated
therapeutically effective
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015511956A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015516450A (ja
JP6116677B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2013/001469 external-priority patent/WO2013170970A1/en
Publication of JP2015516450A publication Critical patent/JP2015516450A/ja
Publication of JP2015516450A5 publication Critical patent/JP2015516450A5/ja
Application granted granted Critical
Publication of JP6116677B2 publication Critical patent/JP6116677B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015511956A 2012-05-18 2013-05-16 （１ｒ，４ｒ）−６’−フルオロ−Ｎ，Ｎ−ジメチル−４−フェニル−４’，９’−ジヒドロ−３’Ｈ−スピロ［シクロヘキサン−１，１’−ピラノ［３，４，ｂ］インドール］−４−アミンおよびオキシカムを含む医薬組成物 Active JP6116677B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12003896.3 2012-05-18
EP12003896 2012-05-18
PCT/EP2013/001469 WO2013170970A1 (en) 2012-05-18 2013-05-16 Pharmaceutical composition comprising (1r,4r)-6'-fluoro-n,n-dimethyl-4-phenyl-4',9'-dihydro-3'h-spiro[cyclohexane-1,1'-pyrano [3,4,b]indol]-4-amine and an oxicam

Publications (3)

Publication Number Publication Date
JP2015516450A JP2015516450A (ja) 2015-06-11
JP2015516450A5 true JP2015516450A5 (enExample) 2017-03-09
JP6116677B2 JP6116677B2 (ja) 2017-04-19

Family

ID=48470899

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015511956A Active JP6116677B2 (ja) 2012-05-18 2013-05-16 （１ｒ，４ｒ）−６’−フルオロ−Ｎ，Ｎ−ジメチル−４−フェニル−４’，９’−ジヒドロ−３’Ｈ−スピロ［シクロヘキサン−１，１’−ピラノ［３，４，ｂ］インドール］−４−アミンおよびオキシカムを含む医薬組成物

Country Status (22)

Country Link
US (1) US9308196B2 (enExample)
EP (1) EP2849746B1 (enExample)
JP (1) JP6116677B2 (enExample)
CN (2) CN108451956A (enExample)
AU (1) AU2013262076B2 (enExample)
BR (1) BR112014028569A2 (enExample)
CA (1) CA2873863A1 (enExample)
CY (1) CY1119824T1 (enExample)
DK (1) DK2849746T3 (enExample)
EA (1) EA026719B1 (enExample)
ES (1) ES2659948T3 (enExample)
HR (1) HRP20171843T1 (enExample)
HU (1) HUE035122T2 (enExample)
IL (1) IL235652B (enExample)
LT (1) LT2849746T (enExample)
MX (1) MX354685B (enExample)
NO (1) NO2849746T3 (enExample)
PL (1) PL2849746T3 (enExample)
PT (1) PT2849746T (enExample)
RS (1) RS56830B1 (enExample)
SI (1) SI2849746T1 (enExample)
WO (1) WO2013170970A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107427493A (zh) 2015-01-23 2017-12-01 格吕伦塔尔有限公司 用于治疗肝功能受损和/或肾功能受损的受试者的疼痛的Cebranopadol
MX2018010367A (es) 2016-02-29 2018-12-10 Guenenthal Gmbh Titulacion de cebranopadol.
GB202405898D0 (en) * 2024-04-26 2024-06-12 Univ Surrey Mycobacterial infections

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0068838B1 (en) 1981-06-26 1986-09-17 The Upjohn Company Analgesic process and composition
US4389393A (en) 1982-03-26 1983-06-21 Forest Laboratories, Inc. Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose
US4765989A (en) 1983-05-11 1988-08-23 Alza Corporation Osmotic device for administering certain drugs
US4783337A (en) 1983-05-11 1988-11-08 Alza Corporation Osmotic system comprising plurality of members for dispensing drug
US4612008A (en) 1983-05-11 1986-09-16 Alza Corporation Osmotic device with dual thermodynamic activity
ES2098264T3 (es) 1989-05-22 1997-05-01 Biochemical Veterinary Res Sales metalicas divalentes de indometacina.
US5472711A (en) 1992-07-30 1995-12-05 Edward Mendell Co., Inc. Agglomerated hydrophilic complexes with multi-phasic release characteristics
US5330761A (en) 1993-01-29 1994-07-19 Edward Mendell Co. Inc. Bioadhesive tablet for non-systemic use products
US5455046A (en) 1993-09-09 1995-10-03 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems for insoluble drugs
US5399362A (en) 1994-04-25 1995-03-21 Edward Mendell Co., Inc. Once-a-day metoprolol oral dosage form
US5914129A (en) 1996-07-23 1999-06-22 Mauskop; Alexander Analgesic composition for treatment of migraine headaches
RS49982B (sr) * 1997-09-17 2008-09-29 Euro-Celtique S.A., Sinergistička analgetička kombinacija analgetičkog opijata i inhibitora ciklooksigenaze-2
EA004032B1 (ru) * 1998-09-10 2003-12-25 Нюкомед Данмарк А/С Фармацевтические композиции лекарственных веществ с быстрым высвобождением
EP1219304B1 (de) 2000-12-28 2004-10-20 Fresenius Kabi Austria GmbH Stabile Infusionslösung von Diclofenac-Salzen, deren Herstellung und Verwendung
ATE359827T1 (de) 2002-06-17 2007-05-15 Chiesi Farma Spa Prozess für die vorbereitung von piroxicam: beta- cyclodextrin einschlusskomplexe
AR040778A1 (es) * 2002-08-06 2005-04-20 Glaxo Group Ltd Anticuerpos alterados o fragmentos funcionales que se unen a mag (glicoproteina asociada a mielina).
DE10252667A1 (de) * 2002-11-11 2004-05-27 Grünenthal GmbH Spirocyclische Cyclohexan-Derivate
DE10257824B4 (de) 2002-12-10 2004-11-11 Kochem, Hans-Günter, Dr. Zusammensetzung zur Schmerzbehandlung, insbesondere zur Behandlung von Gelenkschmerzen
US20100297252A1 (en) 2003-03-03 2010-11-25 Elan Pharma International Ltd. Nanoparticulate meloxicam formulations
US7132452B2 (en) 2003-03-10 2006-11-07 Fang-Yu Lee Topical formulation having effects on alleviating pain/inflammation caused by herpes virus infection
DE10360792A1 (de) 2003-12-23 2005-07-28 Grünenthal GmbH Spirocyclische Cyclohexan-Derivate
AU2006257274A1 (en) 2005-06-17 2006-12-21 Pfizer Inc. Alpha-(aryl-or heteroaryl-methyl)-beta piperidino propanamide compounds as ORL1-receptor antagonists
CN102675136B (zh) * 2006-04-28 2016-01-20 格吕伦塔尔有限公司 包含3-(3-二甲基氨基-1-乙基-2-甲基-丙基)-苯酚和nsaid的药物组合物
CN101147735A (zh) 2006-09-19 2008-03-26 沈阳华泰药物研究有限公司 注射用药物组合物及其药盒
DE102006046745A1 (de) 2006-09-29 2008-04-03 Grünenthal GmbH Gemischte ORL1/µ-Agonisten zur Behandlung von Schmerz
DE102006056458A1 (de) 2006-11-28 2008-05-29 Grünenthal GmbH Arzneimittelzubereitung von Tramadol und Acetaminophen
CN100560061C (zh) 2008-06-20 2009-11-18 海南锦瑞制药股份有限公司 一种氯诺昔康冻干粉针剂及其制备方法
WO2010025931A2 (en) * 2008-09-05 2010-03-11 Grünenthal GmbH Pharmaceutical combination
CA2735139A1 (en) * 2008-09-05 2010-03-11 Petra Bloms-Funke Pharmaceutical combination comprising 6-dimethylaminomethyl-1-(3-methoxy-phenyl)-cyclohexane-1,3-diol and an nsaid
EP3459533A1 (en) * 2010-08-04 2019-03-27 Grünenthal GmbH Pharmaceutical dosage form comprising 6'-fluoro-(n-methyl- or n,n-dimethyl-)-4-phenyl-4',9'-dihydro-3'h-spiro[cyclohexane-1,1'-pyrano[3,4,b]indol]-4-amine for the treatment of nociceptive pain
RU2589831C2 (ru) * 2010-08-04 2016-07-10 Грюненталь Гмбх ЛЕКАРСТВЕННАЯ ДОЗИРОВАННАЯ ФОРМА, КОТОРАЯ СОДЕРЖИТ 6'-ФТОР-(N-МЕТИЛ- ИЛИ N, N-ДИМЕТИЛ-)-4-ФЕНИЛ-4', 9'-ДИГИДРО-3'Н-СПИРО[ЦИКЛОГЕКСАН-1, 1'-ПИРАНО[3, 4, b]ИНДОЛ]-4-АМИН
AR082559A1 (es) * 2010-08-04 2012-12-19 Gruenenthal Gmbh Forma de dosificacion farmaceutica que comprende 6’-fluoro-(n-metil- o n,n-dimetil)-4’-fenil-4’,9’-dihidro-3’h-espiro[ciclohexan-1,1’-pirano[3,4,b]indol]-4-amina

Similar Documents

Publication Publication Date Title
MX2024010140A (es) Nuevos metodos.
HRP20200600T1 (hr) Tapentadol za sprječavanje i liječenje depresije i tjeskobe
JP2016518337A5 (enExample)
BR112013032122A2 (pt) liberação modificada de 4-metil-3-[[4-(3-piridinil)-2-pirimidinil]amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluorometil)fenil] benzamida solubilizada usando ácidos orgânicos
MX2017010287A (es) Composiciones farmaceuticas que comprenden n-(3,5-dimetoxifenil)-n '-(1-metiletil)-n-[3-(1-metil-1h-pirazol-4-il)quinoxalin-6-il]eta no-1,2-diamina.
JP2010222367A5 (enExample)
JP2016053040A5 (enExample)
MX383665B (es) Composiciones de donepezilo y métodos para tratar la enfermedad de alzheimer.
JP2015523407A5 (enExample)
JP2015057451A5 (enExample)
JP2015516452A5 (enExample)
JP2016512817A5 (enExample)
CA3010568A1 (en) Oromucosal nanofiber carriers for therapeutic treatment
HRP20241716T1 (hr) Postupci liječenja promjena u ponašanju
BR112015029894A2 (pt) forma de dosagem farmacêutica sólida
CN110062628A (zh) 一种瑞卡帕布口服缓控释药物组合物及其用途
JP2015516449A5 (enExample)
UA118474C2 (uk) (s)-пірліндол та його фармацевтично прийнятні солі для застосування в медицині
WO2019004788A3 (ko) 브라우쏘칼콘 a를 유효성분으로 포함하는 염증성 장질환 예방 또는 치료용 약학 조성물
JP2017513944A5 (enExample)
BR112014004737A2 (pt) composto de composição de cloridrato de ambroxol e método de preparação do composto
JP2015516451A5 (enExample)
CL2016000182A1 (es) Composición farmacéutica anti-tuberculosis estable en una forma de un comprimido recubierto que comprende gránulos de isoniazid y gránulos de rifapentina y su proceso de preparación
CL2016000183A1 (es) Composición farmacéutica anti-tuberculosis estable en una forma de un comprimido redispersable que comprende gránulos de isoniazid y gránulos de rifapentina y su proceso de preparación
ECSP15025868A (es) Composición que comprende un extracto purificado aíslado de pseudolysimachion rotundum var. subintegrum que contiene una cantidad abundante de ingrediente activo o los compuestos aislados del mismo, como un ingrediente activo para prevenir/tratar la enfermedad pulmonar obstructiva crónica, y su uso